If you have been reading about thymosin alpha 1 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-05-28. Where a claim depends on a specific study, the study is described rather than over-claimed.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Identity and purity are assessed with a small set of standard peptide methods. Reversed-phase high-performance liquid chromatography separates the main peak from truncated or oxidized species, and its area percentage is the usual purity measure. Mass spectrometry confirms the observed molecular mass against the expected value, while amino acid analysis or peptide mapping checks composition and sequence. Specifications for research-grade material are often stated as 95 percent or higher, though the exact limit depends on the supplier and the intended use.
Laboratory supplies of the peptide usually arrive as a lyophilized powder in sealed vials. The powder is hygroscopic, so a vial should be allowed to reach room temperature before it is opened to prevent condensation on the contents. Weighing and transfer are best performed in a low-humidity environment with clean tools. Once dissolved, the solution should be mixed gently rather than vortexed, because foaming and shear can reduce recovery of the peptide.
Storage recommendations center on low temperature, dryness, and protection from repeated freezing and thawing. The intact powder is commonly held at 20 degrees below zero Celsius or colder, while a working solution is divided into single-use aliquots to limit freeze-thaw cycles. Buffered saline or phosphate-buffered saline at neutral pH is frequently used as a diluent. Light sensitivity is not well documented, yet amber vials or foil wrapping are common practice for long-term storage of peptide stocks.
| Property | Value | Notes |
|---|---|---|
| First described | 1977 | Reported as a component of thymosin fraction 5 |
| Sequence length | 28 amino acids | N-terminal residue is acetylated |
| Net charge at neutral pH | Negative | Reflects a high proportion of acidic residues |
| Principal studied uses | Chronic hepatitis B and vaccine adjuvant | Research uses outnumber approved indications |
| Regulatory status | Approved in a limited number of countries | Not approved in the United States or most of Europe |
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
胸腺素α1对免疫系统的影响涉及多种细胞类型。研究表明，它可促进未成熟T细胞向成熟T细胞分化，并增强T细胞对抗原刺激的增殖反应。树突状细胞在Tα1存在下表达更高水平的共刺激分子，从而更有效地呈递抗原。此外，自然杀伤细胞的活性也观察到上升。这些效应并非直接杀伤病原体，而是调节宿主免疫应答的强度与方向。
在信号层面，Tα1可能通过Toll样受体等模式识别受体发挥作用。部分实验显示，它能激活髓样分化因子88依赖的通路，进而促进核因子κB进入细胞核。这导致白细胞介素2、干扰素γ和白细胞介素12等细胞因子的转录增加。这些细胞因子偏向辅助性T细胞1型应答，有助于细胞免疫。然而，具体受体和结合位点尚未完全确定，不同实验模型的结果存在差异。
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Quality control for thymosin alpha-1 focuses on identity, purity, and potency. Identity is confirmed by mass spectrometry and amino acid analysis, while purity is assessed by chromatography with limits on related substances and residual solvents. Potency assays may use cell-based immune readouts, but these are not standardized across laboratories. Regulatory status differs by jurisdiction; no product is approved in the United States for clinical use, whereas some other countries register injectable forms for specific indications.
Quantifying thymosin alpha-1 in a sample usually relies on reverse-phase high-performance liquid chromatography. The peptide lacks strong chromophores, so detection often occurs at 214 nm, where the peptide backbone absorbs. Mass spectrometry provides confirmatory identification and can detect sequence variants or truncations. Immunoassays have been used in biological matrices, but they may cross-react with related fragments. For purity assessment, chromatographic peak area gives the main component percentage, while mass accuracy verifies molecular identity.
The lyophilized peptide is generally stable for extended periods when kept cold and dry. Once dissolved, aqueous solutions are less stable; hydrolysis, oxidation, and aggregation can degrade the material. Storage at -20 °C or lower slows these processes. Repeated freeze-thaw cycles are best avoided because they can promote aggregation. The exact shelf life depends on formulation, pH, and concentration, so stability studies are typically performed for each specific product.
Scanning Electron Microscope (SEM) Transmission electron Microscope (TEM) Fourier Transform Infrared Spectroscopy (FTIR) Atomic force microscopy Contact angle meter Zeta potential (streaming potential) X-ray Diffraction (XRD) Liquid–Liquid Displacement Porosimetry (LLDP)
November 1972); novelist, editor; placed 60th on the Independent on Sunday Pink List 2007; professor of creative writing at Royal Holloway, University of London; correspondent at the New Yorker; became a Fellow of the Royal Society of Literature in 2018; awards and nominations include John Llewellyn Rhys Prize, Somerset Maugham Award, Sunday Times 'Young Writer of the Year (shortlisted), London Arts New London Writers' Award, K. Blundell Trust Award, Le Prince Maurice Roman d'Amour Prize (shortlisted), Geoffrey Faber Memorial Prize (shortlisted), Man Booker Prize 2013 (longlisted) Baileys Women's Prize for Fiction 2014 (longlisted), Women's Prize for Fiction 2022 (longlisted for The Exhibitionist) Heather Mendick, Labour activist previously appointed as Jeremy Corbyn's Jewish liaison officer; former Hackney South constituency Labour party secretary, academic, previously Reader in Education at Brunel University and author of scholarly texts and monographs on educational theory, semantics, science, contemporary culture, ontology, ideology and epistemology, published by Routledge and McGraw Hill Education Farah Mendlesohn (b. 27 July 1968) is a British academic historian, best known for her writings on science fiction and fantasy. Gerard Menuhin, son of Yehudi Menuhin; grandson of leading anti-Zionist activist and scholar, Moshe Menuhin, and from the ancestral lineage of Rabbi Shneur Zalman of Liadi, the founder of Chabad Hassidism as well as Rabbi Levi Yitzchok of Berditchev.
== Honors and awards == Diamandis is a member of the Academy of Athens and the Royal Society of Canada. He is also a fellow of the American Association for the Advancement of Science, the Canadian Academy of Health Sciences, and the Royal College of Physicians and Surgeons of Canada. From the American Association for Clinical Chemistry, he has received the Morton K. Schwartz Award for Significant Contributions in Cancer Research Diagnostics, among other awards; he is also a member of the Association's Hall of Fame.
== Use in antibody-drug conjugates == A new antibody-drug conjugate (ADC) technology based on α-amanitin has shown activity in therapy-resistant tumor cells, e.g. cells expressing multi-drug resistant transporters, tumor-initiating cells and non-dividing cells at picomolar concentrations. The unique mode of action of α-amanitin seems to make the amanitin-based ADCs a suitable toxic payload. This toxin has a water-soluble structure, resulting in ADCs with low tendency for aggregation. Significant clinical advances occurred in 2025 and 2026 with Heidelberg Pharma’s lead candidate HDP-101 (pamlectabart tismanitin), a BCMA-targeted amanitin-based antibody-drug conjugate (ATAC) for relapsed or refractory multiple myeloma. In the ongoing Phase I/IIa trial (NCT04879043), dose escalation proceeded safely up to 218 µg/kg without reaching a maximum tolerated dose, and the recommended Phase IIa dose was selected in April 2026. The program received FDA Fast Track designation in October 2025. In the higher-dose cohorts (90–140 µg/kg), overall response rates reached 38–57 %, with several heavily pretreated patients, including those who had failed prior BCMA-directed therapies, achieving stringent complete remissions lasting more than one year. The safety profile remained favorable, with mostly mild-to-moderate and manageable adverse events and no clinically relevant hepatotoxicity, ocular toxicity, or renal impairment.
Involvement of lipid peroxidation chain reaction in atherogenesis triggered research on the protective role of the heavy isotope (deuterated) polyunsaturated fatty acids (D-PUFAs) that are less prone to oxidation than ordinary PUFAs (H-PUFAs). PUFAs are essential nutrients – they are involved in metabolism in that very form as they are consumed with food. In transgenic mice, a model for human-like lipoprotein metabolism, adding D-PUFAs to the diet reduced body weight gain, improved cholesterol handling, and reduced atherosclerotic damage to the aorta.
Sources: en.wikipedia.org
Hyaline cartilage is the glass-like (hyaline) and translucent cartilage found on many joint surfaces. It is also most commonly found in the ribs, nose, larynx, and trachea. Hyaline cartilage is pearl-gray in color, with a firm consistency and has a considerable amount of collagen. It contains no nerves or blood vessels, and its structure is relatively simple.
Kr + F2 → KrF2 Krypton gas in a krypton fluoride laser absorbs energy from a source, causing the krypton to react with fluorine gas, producing the exciplex krypton fluoride, a temporary complex in an excited energy state:
=== Prey === Rattlesnakes typically consume mice, rats, rabbits, ground squirrels, gophers, prairie dogs, ground-nesting birds and other small animals (such as lizards, frogs, toads and occasionally American mink and weasels). They lie in wait for their prey, or hunt for it in holes. The rattlesnake's defence and hunting mechanisms are bound to its physiology and its environment. More importantly environmental temperature can influence the ability of ectotherms. The prey is killed quickly with a venomous bite as opposed to constriction. If the bitten prey moves away before dying, the rattlesnake can follow it by its scent. When it locates the fallen prey, it checks for signs of life by prodding with its snout, flicking its tongue, and using its sense of smell. Once the prey has become incapacitated, the rattlesnake locates its head by odors emitted from the mouth. The prey is then ingested head first, which allows wings and limbs to fold at the joints in a manner that minimizes the girth of the meal. The gastric fluids of rattlesnakes are extremely powerful, allowing for the digestion of flesh and bone. Optimal digestion occurs when the snake maintains a body temperature between 80 and 85 °F (27 and 29 °C). If the prey is small, the rattlesnake often continues hunting. If the meal was adequate, the snake finds a warm, safe location in which to coil up and rest until the prey is digested. Feeding habits play an important ecological role by limiting the size of rodent populations, which prevents crop damage and stabilizes ecosystems.
Liu Wenhui travelled to Chongqing to negotiate with Liu Xiang, but Liu Xiang would not hand over the confiscated shipment. This was because Liu Xiang had a policy of not allowing any other Sichuanese warlord to gain aircraft (he himself had already acquired a rudimentary air force consisting of several Potez 25 and Breguet 14 bombers). Western sources also agree that Liu Wenhui tried obtaining aircraft, although according to them the aircraft were either seized in Hankou by the central government or crashed en route to Chengdu. The Chinese sources go further by asserting that in May 1931, Liu Wenhui attempted to bribe Liu Xiang's subordinates, including Fan Shaozhen, to join him, but they reported this matter to Liu Xiang, causing Liu to waste 450,000 yuan. An angered Liu supposedly then cut off Liu Xiang's grain supply, forcing the Chongqing warlord to urgently purchase grain from Hunan to prevent hunger. Whatever the matter, it is clear that Liu Wenhui's once-cooperative relationship with his nephew, General Liu Xiang, had soured and turned into a rivalry. On 19 October 1932, Liu Xiang's general, Tang Shizun, and ninety-four other Sichuanese warlords issued a circular telegram to denounce Liu Wenhui. The telegram asserted that Liu was power-hungry, unscrupulous, corrupt, and nepotistic, with no real plans for governing Sichuan and resorting to underhanded tactics such as bribery, backstabbing, and banditry to gain and maintain power. On the eve of war in 1932, Liu Wenhui's armies were estimated at around 120,000 men, slightly outnumbering Liu Xiang's 100,000.
Sources: en.wikipedia.org
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.
Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.
Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.
Aliquots are typically frozen well below zero Celsius and thawed only once, since repeated cycles promote aggregation and loss. Dilution into a neutral buffer limits degradation during short working periods, and prolonged storage at room temperature is avoided.